Podcast

The Evidence Based Rheumatology Podcast

Author: Michael Putman
Feed episode count: 100
Official site: https://msputman.podbean.com
RSS: https://feed.podbean.com/msputman/feed.xml
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175.md

Summary

A podcast for physicians about evidence based medicine in rheumatology. Each week we'll critique and apply a paper in the medical literature.

Episodes

Jul 24, 2026 · not_requested

E138: Dapirolizumab for SLE (PHOENYCS-GO)

Duration seconds: 1329
Source: https://msputman.podbean.com/e/e138-dapirolizumab-for-sle-phoenycs-go/

HTML Markdown JSON

Jun 29, 2026 · not_requested

E137: Obexelimab in IgG4-RD (INDIGO)

Duration seconds: 936
Source: https://msputman.podbean.com/e/e137-obexelimab-in-igg4-rd-indigo/

HTML Markdown JSON

Jun 15, 2026 · not_requested

E136: Secukinumab in PMR (REPLENISH)

Duration seconds: 819
Source: https://msputman.podbean.com/e/e136-secukinumab-in-pmr-replenish/

HTML Markdown JSON

Apr 30, 2026 · not_requested

E135: IL17 and a GLP1?

Duration seconds: 663
Source: https://msputman.podbean.com/e/e135-il17-and-a-glp1/

HTML Markdown JSON

Apr 17, 2026 · not_requested

E134: Brepocitinib in Dermatomyositis (VALOR)

Duration seconds: 898
Source: https://msputman.podbean.com/e/e134-brepocitinib-in-dermatomyositis-valor/

HTML Markdown JSON

Mar 19, 2026 · not_requested

E133: Obinutuzumab for SLE (ALLEGORY)

Duration seconds: 921
Source: https://msputman.podbean.com/e/e133-obinutuzumab-for-sle-allegory/

HTML Markdown JSON

Mar 5, 2026 · not_requested

E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)

Duration seconds: 834
Source: https://msputman.podbean.com/e/e132-romosozumab-vs-teriparatide-for-osteoproosis-structure/

HTML Markdown JSON

Jan 21, 2026 · not_requested

E131: A Sham-Controlled Sham of a Trial: RESET-RA

Duration seconds: 888
Source: https://msputman.podbean.com/e/e131-a-sham-controlled-sham-of-a-trial-reset-ra/

HTML Markdown JSON

Dec 22, 2025 · not_requested

E130: Telitacicept for SLE

Duration seconds: 786
Source: https://msputman.podbean.com/e/e130-telitacicept-for-sle/

HTML Markdown JSON

Dec 4, 2025 · not_requested

E129: Long Term Routine Laboratory Monitoring in RA

Duration seconds: 917
Source: https://msputman.podbean.com/e/e129-long-term-routine-laboratory-monitoring-in-ra/

HTML Markdown JSON

Nov 12, 2025 · not_requested

E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

Duration seconds: 1143
Source: https://msputman.podbean.com/e/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild/

HTML Markdown JSON

Sep 22, 2025 · not_requested

E127: TNFs and All That CHF

Duration seconds: 1306
Source: https://msputman.podbean.com/e/e127-tnfs-and-all-that-chf/

HTML Markdown JSON

Sep 8, 2025 · not_requested

E126: Risk Signals, JAKs, and SELECTIVE-ity

Duration seconds: 874
Source: https://msputman.podbean.com/e/e126-risk-signals-jaks-and-selective-ity/

HTML Markdown JSON

Jun 29, 2025 · not_requested

E125: Adrenal Insufficiency after Stopping Prednisone

Duration seconds: 1072
Source: https://msputman.podbean.com/e/e125-adrenal-insufficiency-after-stopping-prednisone/

HTML Markdown JSON

Jun 12, 2025 · not_requested

e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study

Duration seconds: 858
Source: https://msputman.podbean.com/e/e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study/

HTML Markdown JSON

Apr 30, 2025 · not_requested

E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA

Duration seconds: 1093
Source: https://msputman.podbean.com/e/e123-upadacitinib-for-giant-cell-arteritis-select-gca/

HTML Markdown JSON

Apr 17, 2025 · not_requested

E122: Guidelines for Maybe Diagnosing HLH

Duration seconds: 678
Source: https://msputman.podbean.com/e/e122-guidelines-for-maybe-diagnosing-hlh/

HTML Markdown JSON

Apr 2, 2025 · not_requested

E121: Obinutuzumab in SLE-LN

Duration seconds: 1094
Source: https://msputman.podbean.com/e/e121-obinutuzumab-in-sle-ln/

HTML Markdown JSON

Mar 6, 2025 · not_requested

E120: Real Life Use of PEXIVAS-Low

Duration seconds: 1473
Source: https://msputman.podbean.com/e/e120-real-life-use-of-pexivas-low/

HTML Markdown JSON

Feb 10, 2025 · not_requested

E119: Teclistamab for Rheumatology Writ Large

Duration seconds: 652
Source: https://msputman.podbean.com/e/e119-teclistamab-for-rheumatology-writ-large/

HTML Markdown JSON

Jan 31, 2025 · not_requested

E118: The emerging risk of overdiagnosis in RA and PMR

Duration seconds: 962
Source: https://msputman.podbean.com/e/e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr/

HTML Markdown JSON

Dec 3, 2024 · not_requested

E117: Inebilizumab for IgG4-RD (MITIGATE)

Duration seconds: 775
Source: https://msputman.podbean.com/e/e117-inebilizumab-for-igg4-rd-mitigate/

HTML Markdown JSON

Nov 11, 2024 · not_requested

E116: A New Paradigm for PMR

Duration seconds: 569
Source: https://msputman.podbean.com/e/e116-a-new-paradigm-for-pmr/

HTML Markdown JSON

Oct 28, 2024 · not_requested

E115: Benralizumab for EGPA - the MANDARA Study

Duration seconds: 592
Source: https://msputman.podbean.com/e/e115-benralizumab-for-egpa-the-mandara-study/

HTML Markdown JSON

Oct 14, 2024 · not_requested

E114: Target Trials and STAR-RA with Rishi Desai

Duration seconds: 1875
Source: https://msputman.podbean.com/e/e114-target-trials-and-star-ra-with-rishi-desai/

HTML Markdown JSON